Drug Profile
Recombinant human alkaline phosphatase - AMRIF/CEVEC
Alternative Names: hRESCAP; Recombinant human placental alkaline phosphatase; rhuAP; rhuAP-CAP cell; Theraptech projectLatest Information Update: 10 Oct 2022
Price :
$50
*
At a glance
- Originator Alloksys Life Sciences; CEVEC Pharmaceuticals
- Developer AMRIF; CEVEC Pharmaceuticals
- Class Anti-inflammatories; Anti-ischaemics; Hepatoprotectants; Phosphoric monoester hydrolases; Recombinant proteins
- Mechanism of Action Cytokine modulators; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Rheumatoid arthritis
Most Recent Events
- 06 Oct 2022 CEVEC Pharmaceuticals has been acquired by Cytiva
- 16 Jul 2016 No recent reports of development identified for phase-I development in Rheumatoid-arthritis(In volunteers) in Netherlands (Parenteral)
- 13 Jan 2014 Recombinant human alkaline phosphatase - AMRIF/CEVEC is available for licensing. http://www.alloksys.com